CircNova Future of Health
Detroit, US · 5 known investors
CircNova uses artificial intelligence to generate, analyze, and identify circular RNA structures for therapeutic development. The company focuses on non-coding RNA therapeutics targeting previously undruggable disease targets and major unmet clinical needs.
Also known as CircNova · Novarna
Founders & leadership
Investors · 5
Company profile
researched Aug 2026CircNova, which operates the Novarna platform, applies artificial intelligence to the design of RNA therapeutics. The platform is organized around two components operated as a closed feedback loop: NovaEngine, an AI design system purpose-built for RNA, and NovaLab, an in-house wet lab that validates AI-generated candidates and feeds experimental results back into model training.
NovaEngine is described as a fourth-generation AI system that generates entirely novel RNA sequences optimized for a specified target, rather than only predicting properties of existing sequences. Stated capabilities include 3D RNA tertiary structure prediction, RNA:target interaction modeling, novel sequence generation (NovaGen), folding and docking prediction (DeepFoldRNA, NovaFold_2D) and feature enrichment (NovaFM). NovaLab handles mapping and synthesis of AI-generated candidates, functional validation in cellular assays, in vitro experimentation, pooled screening and structural characterization, generating proprietary experimental data used to retrain the models.
The company positions the approach against conventional RNA drug discovery, which it characterizes as dependent on iterative screening, trial-and-error synthesis and lengthy, costly wet lab cycles.
Business model
Design-as-a-Service engagements in which CircNova designs RNA candidates against a customer-supplied target, structured across three tiers: Rapid Discovery (a focused pilot against a specific target for proof-of-concept and platform validation), Optimized Lead (extended design and validation cycles delivering preclinical-ready optimized candidates) and Discovery Partnership (multi-year co-development).
Service-based engagements scoped per target, with multi-year discovery partnerships carrying milestone and royalty structures spanning discovery through commercialization.
Traction
In a collaboration with the University of Michigan DiFeo Lab, CircNova designed RNA candidates against an ovarian cancer target that the DiFeo Lab tested in its own facility; the company reports the designs outperformed a commercially available treatment for the same target, produced patent-eligible compositions and demonstrated multifunction RNA design capability.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positioned within AI-driven RNA drug discovery, targeting the design stage of RNA therapeutic development.
The company frames its distinction as designing RNA sequences de novo rather than only predicting properties of existing candidates, and as owning proprietary experimental data generated by its own wet lab that it states cannot be replicated with external datasets.
Technology
A generative AI design engine for RNA (NovaEngine) coupled to an in-house wet lab (NovaLab) in a design-build-test-learn loop. Model capabilities span novel RNA sequence generation, 3D tertiary structure prediction, folding and docking prediction, RNA:target interaction modeling and feature enrichment; wet lab outputs including cellular assay validation, in vitro experimentation, pooled screening and structural characterization are used as training signal for subsequent model iterations.
Go-to-market
Direct engagement with prospective partners' scientific teams, who submit a target for which CircNova scopes a program; validation work with academic collaborators, such as the University of Michigan DiFeo Lab, is used as external evidence of platform performance.
Organizations pursuing RNA therapeutic programs against defined biological targets, including academic research laboratories and drug developers seeking pilot validation, optimized preclinical-ready leads or multi-year co-development partnerships.
Geography
Headquartered in Detroit, United States, with a collaboration in Michigan at the University of Michigan DiFeo Lab.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 2
by search overlap
Companies competing with CircNova Future of Health for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsNovarna designed RNA candidates against an ovarian cancer target; the DiFeo Lab at the University of Michigan tested them in its own facility and reported that the designs outperformed a commercially available treatment for the same target and yielded new molecule types with patent potential.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- CircNova Future of Healthcircnova.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does CircNova Future of Health do?
- CircNova runs Novarna, a generative AI platform paired with an in-house wet lab to design novel RNA therapeutic candidates.
- Who are CircNova Future of Health's investors?
- CircNova Future of Health's investors include 100Km Ventures Llc, ID Ventures, Michigan Rise, Service Provider Capital, South Loop Ventures.
- Where is CircNova Future of Health headquartered?
- CircNova Future of Health is headquartered in Detroit, US.